Liquidia is a late-stage clinical biopharmaceutical company that focuses on the development and commercialization of various products using its PRINT technology that enables precise production of drug particles designed to enhance the safety, efficacy, and performance of a range of therapies. It was founded in 2004 and is based in Morrisville, North Carolina.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential
Liquidia news
12.05.2022
Liquidia's GAAP loss for 3 months of 2022 was $15.943 million, up 73.6% from $9.183 million in the prior year. Revenue increased 13.2% to $3.492 million compared to $3.084 million a year earlier.
Source: 
investors.liquidia.com
investors.liquidia.com
17.03.2022
Liquidia's GAAP loss for 2021 was $34.579 million, down 42.1% from $59.763 million the previous year. Revenue increased 17.4 times to $12.853 million from $0.739 million a year earlier.
Source: investors.liquidia.com
investors.liquidia.com
05.11.2021
Liquidia's GAAP loss for 9M 2021 was $23.016 mln. 2021 was $23.016 million, down 47.3% from $43.676 million in the previous year. Revenues were $9.638 million. The company did not generate revenues a year earlier.
Source: investors.liquidia.com
investors.liquidia.com
10.08.2021
Liquidia's GAAP loss for 6M 2021 was $15.735 million, down 45.2% from $28.708 million in the prior year. Revenue was $6.459 million. A year earlier, the company had generated no revenue.
Source: investors.liquidia.com
investors.liquidia.com
General information
| Company name | Liquidia |
|---|---|
| Tags | #pharmacy, #biotechnology |
| Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology |
| Business address | 419 Davis Drive Suite 100 Morrisville, NC 27560 United States |
| Mailing address | 419 Davis Drive Suite 100 Morrisville, NC 27560 United States |
| Website | www.liquidia.com |
| Information disclosure | www.sec.gov |
English (US) 